Purdue Pharma L.P.

Track this case

Case Number:

7:19-bk-23649

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. February 17, 2022

    Purdue Gets OK For 2-Week Opioid Suit Freeze Extension

    A New York bankruptcy judge Thursday gave Purdue Pharma a two-week extension on an injunction pausing litigation against the company after being told the drugmaker is closing in on an agreement for a new Chapter 11 plan.

  2. February 09, 2022

    NY Judge OKs Canadian Entities' Late Purdue Ch. 11 Appeal

    A New York federal judge on Wednesday approved a belated appeal filed by Canadian entities challenging Purdue Pharma's Chapter 11 plan, hours after Purdue said it had no problem with the appeal going forward before the Second Circuit.

  3. February 08, 2022

    Canadian Entities Seek Late Appeal In Purdue Ch. 11 Case

    Canadian entities are seeking permission to file a late appeal to a New York federal court ruling that vacated Purdue Pharma's Chapter 11 plan, saying Tuesday there are unresolved issues related to their claims that won't be covered by the drugmaker's challenge in the Second Circuit.

  4. February 04, 2022

    Purdue Asks For New Extension On Opioid Suit Freeze

    Purdue Pharma has asked a New York bankruptcy judge for another extension on the opioid litigation injunction that has been in place since it filed for bankruptcy, citing word that a settlement agreement is near on a modified reorganization plan and the considerable work that would follow.

  5. February 01, 2022

    Purdue Closing In On New Ch. 11 Deal With Sackler Family

    A New York bankruptcy judge extended a mediation deadline Tuesday in the Chapter 11 case of Purdue Pharma after the mediator reported the parties were close to a deal that would see members of the Sackler family significantly increase their more than $4.3 billion in payments under the debtor's scuttled plan.

  6. January 03, 2022

    A Blockbuster Year Ahead For Health, Life Sciences Litigation

    Health care and life sciences litigation is already red hot as 2022 begins and appears all but certain to intensify throughout the year as the clock ticks on time-sensitive lawsuits, the U.S. Supreme Court nears the end of its current term and opioid cases generate more trials and fresh drama. Here, Law360 explores five key litigation areas to watch.

  7. December 06, 2021

    Sackler Family Denies Pre-Ch. 11 Looting Of Purdue Pharma

    Members of the Sackler family who own drugmaker Purdue Pharma told a New York federal judge Monday that they did not increase transfers of cash out of the business in the run-up to its 2019 Chapter 11 filing, and instead left the company with more unrestricted cash than ever before at that time.

  8. November 18, 2021

    Purdue Cleared To Pay Gov't Groups Over $12M In Ch. 11 Fees

    A New York bankruptcy judge approved a request from drugmaker Purdue Pharma LP to reimburse more than $12 million in fees incurred by groups representing government entities in its Chapter 11 plan mediation process, saying the groups made significant contributions to the confirmed plan.

  9. November 09, 2021

    Purdue Agrees Not To Finalize Ch. 11 Plan Until Appeals Done

    A New York bankruptcy judge said Tuesday that a stay of the implementation of Purdue Pharma's Chapter 11 plan pending appeals was unnecessary after Purdue agreed not to take the plan's final steps until after the first round of appeals are decided.

  10. October 25, 2021

    Purdue Opposes Requests To Delay Ch. 11 Plan For Appeals

    Purdue Pharma LP is arguing that delaying the consummation of its Chapter 11 plan to allow appeals to be resolved first would needlessly delay the distribution of billions of dollars for opioid abatement efforts while there was no danger of prejudice to the appellants.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!